Enzyme replacement therapy and renal function in 201 patients with Fabry disease

Clinical Nephrology

Volumn 66, Issue 2, 2006, Pages 77-84

  Schwarting, A ^a   Dehout, F ^b   Feriozzi, S ^c,f,f   Beck, M ^a   Mehta, A ^d   Sunder Plassmann, Gere ^e,f   Bodamer, O ^f   Hauser, A C ^f   Kleinert, J ^f   Binder, C ^f   Kotanko, P ^f   Kroepfl, T ^f   Plecko, B ^f   Clerbaux, G ^f   Georges, B ^f   Nassogne, M C ^f   Pirson, Y ^f   Roland, D ^f   Van Maldergem, L ^f   Goyens, P ^f   Eyskens, F ^f   Bultas, J ^f   Karetova D ^f   Linhart, A ^f   Lubanda, J C ^f   Magage, S ^f   Choukroun, G ^f   Berthelot, J ^f   Carey Reomonnay, S ^f   Lacombe, D ^f   Benziane, S ^f   Hachulla, E ^f   Dussol, B ^f   Jaeger, P ^f   Germain, D ^f   Lidove, O ^f   Jaussaud, R ^f   Caraman, D ^f   von Arnim Baas, A ^f   Hennermann, J ^f   Hoffmann, B ^f   Neumann, H P H ^f   Das, A ^f   Illsinger, S ^f   Baron, K ^f   Delgado Sanchez, S ^f   Hartung, R ^f   Kampmann, C ^f   Whybra, C ^f   Koletzko, B ^f   Bottcher T ^f   Rolfs, A ^f   Gabrielli, O ^f   Salvatori, I F ^f   Concolino, D ^f   Strisciuglio, P ^f   Vega, G ^f   Borsini, W ^f   Buchner, S ^f   Parini, R ^f   Ravaglia, R ^f   Santus, S ^f   Di Vito, R ^f   Burlina, A ^f   Tognana, G ^f   Antuzzi, D ^f   Castorina, N ^f   Di Lillo, M ^f   Ricci, R ^f   Houge, G ^f   Laegreid L M ^f   Stromsvik N ^f   Svarstad, E ^f   Tondel C ^f   Skarbovik A ^f   Tafjord, A B ^f   Barba, M A ^f   Gomez Huertas E ^f   Herrera, J ^f   Ara, J ^f   Bonal, J ^f   Larrousse, E ^f   Pintos, G ^f   Ballarin, J ^f   Torra, R ^f   Torras, J ^f   Torregrosa, V ^f   Gonzalez J ^f   Garcia, M ^f   Herrera, C ^f   Martin, I ^f   Rodriguez, J ^f   Barbado, F J ^f   Garcia Consuegra, J ^f   Garcia de Lorenzo J ^f   Lopez M ^f   Paniagua, J ^f   Hernandez S ^f   more..

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Centre Hospitalier Universitaire de Charleroi   (Belgium)

^c BELCOLLE HOSPITAL   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f NONE

Author keywords

Chronic kidney disease; Creatinine; Enzyme replacement therapy; Fabry disease; Fabry Outcome Survery; Glomerular filtration rate

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LONGITUDINAL STUDY; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ALPHA-GALACTOSIDASE; COHORT STUDIES; CREATININE; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; KIDNEY; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 33747116927     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of Agalsidase-α treatment. Eur J Clin Invest. 2004; 34: 838-844.
2. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin HA, III, Kopp JB. Natural history of Fabry renal disease: influence of α-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002; 81: 122-138.
3. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human α-galactosidase α replacement therapy in Fabry's disease. N Engl J Med. 2001; 345: 9-16.
4. Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005; 42: 247-252.
5. Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group. A simplified equation to predict glomerular filtration rate. J Am Soc. 2000; Nephrol 11: 155A.
6. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001a; 38: 769-775.
7. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001b; 38: 750-760.
8. National Kidney Foundation. National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266.
9. Pastores GM, Thadhani R. Advances in the management of Anderson-Fabry disease: enzyme-replacement therapy. Expert Opinion on Biological Therapy. 2002; 2: 325-333.
10. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO. Infusion of α-galactosidase A reduces tissue globotriaosyl-ceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 2000; 97: 365-370.
11. Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001; 285: 2743-2749.
12. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with Agalsidase-α for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2005; 21: 345-354.